Cala Trio™; The first non-invasive personalized therapy for hand tremors

Translate to Spanish or other 102 languages!

Source information: https://calatrio.com 

Mega Doctor News

- Advertisement -

The first targeted, wearable therapy designed to treat essential tremor (ET). The therapy delivers meaningful results for most patients after just a single session. Cala Trio™ requires a prescription from a medical doctor.

Source information: https://calatrio.com 

The Science

Surface stimulation delivered at your wrist is thought to disrupt the central tremor network in your brain that causes the hand tremor.

- Advertisement -
  • Developed through Clinical Studies
  • 64% of patients reported having persistent relief for an average of 94 minutes
  • 54% of patient’s tremor power improved by at least 50%

See if it’s right for you

A new approach to managing essential tremor

Non-invasive

Source information: https://calatrio.com 

Cala Trio™ is a wrist worn wearable therapy. No surgery or invasive procedures needed.

Drug Free

Source information: https://calatrio.com 

Tremor reduction without systemic side effects and drug interactions. A new individualized solution for essential tremor that fits with the flow of your life.

Easy to Try

Source information: https://calatrio.com 

There is no perfect treatment for everyone. If Cala Trio™ is not right for you, simply return within 60 days for a full refund less the $99 trial fee.

- Advertisement -

Results

The image below is an actual patient test (Archimedes Spiral Task) before and after a 40-minute stimulation therapy with Cala Trio.

Indications for Use

Cala Trio is indicated to aid in the transient relief of hand tremors in the treated hand following stimulation in adults with essential tremor. Please refer to the Safety Information for a complete listing of warnings and cautions.

Caution: Federal law restricts this device to sale by or on the order of a physician.

Visit https://calatrio.com for more information. All information is sourced from this site. 

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

FDA Approves First Factor Xla Inhibitor to Help Prevent Stroke in Certain Adults at High Risk 

The U.S. Food and Drug Administration today approved Sunharbo (asundexian) 50 mg tablets, the first factor XIa (FXIa) inhibitor for use in combination with antiplatelet therapy to reduce the risk of stroke in adults following a recent mild-to-moderate non-cardioembolic ischemic stroke (a stroke caused by a clot that did not originate in the heart) or a high-risk transient ischemic attack (TIA), often called a “mini-stroke.” 

Practical Health Tips to Navigate Cold and Flu Season Safely

With cold and flu season in full swing, experts say there are some simple steps you can take to protect yourself and those around you.

DHR Health Expands Ophthalmology Services with Addition of Dr. Rachel Gelman

 Continuing its mission to provide exceptional medical care to patients across the Rio Grande Valley, DHR Health is pleased to welcome ophthalmologist Dr. Rachel Gelman to its team of healthcare providers.

STHS McAllen Welcomes Aspiring Youth for an Interactive Look Inside Healthcare

As the demand for healthcare professionals continues to grow, introducing young students to the wide range of opportunities available in the medical field is more important than ever. From nurses and physicians to emergency responders, pharmacists and other essential healthcare workers, each plays a critical role in caring for patients and keeping communities healthy.
- Advertisement -